Log In
Print
BCIQ
Print
Print this Print this
 

solitomab (AMG 110) (formerly MT110)

Also known as: formerly anti-Ep-CAM BiTE

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionBispecific T cell engager (BiTE) antibody targeting the epithelial cell adhesion molecule (EpCAM) antigen and CD-3
Molecular Target Epithelial cell adhesion molecule (EpCAM) ; CD3
Mechanism of ActionBinds CD3; Binds epithelial cell adhesion molecule (EpCAM)
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,200.0M

$1,200.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today